Skip to content

Agios Pharmaceuticals AGIO Lease Liability Payments - Due Year Two

Lease Liability Payments - Due Year Two at other companies

Precigen logo
PrecigenPGEN
$1.4M+3.2%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$486K-52.2%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$18.11M+10.1%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.12B+18.1%
Enterprise value$2.04B+15.2%
P/S32.1×-16.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's lease liability payments - due year two.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's lease liability payments - due year two?
Agios Pharmaceuticals (AGIO) reported lease liability payments - due year two of $3.48M in Q1 2026.
How has Agios Pharmaceuticals's lease liability payments - due year two changed year-over-year?
Agios Pharmaceuticals's lease liability payments - due year two decreased by 83.2% year-over-year, from $20.76M to $3.48M.
What does lease liability payments - due year two mean?
This metric identifies the total cash payments required for operating and finance leases in the second year following the current balance sheet date. It helps investors forecast long-term fixed cost commitments and cash flow requirements. It is essential for modeling the company's future solvency and operational leverage.